The Nexera MP UHPLC for LC/MS analysis in drug detection processes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Nexera MP UHPLC for LC/MS analysis in drug detection processes

Shimadzu has introduced the Nexera MP UHPLC as a Front End system for LC/MS. The Nexera MP is perfect for LC/MS analysis conducted in pharmacokinetics and synthesis stages in drug detection processes.

The new SIL-30ACMP Multiplate Autosampler used in the Nexera MP is best suited for LC/MS analysis and has the industry-best micro-volume injection repeatability, the world’s highest injection speed and the lowest carryover. Combining the Nexera MP with Shimadzu’s LCMS-8030 Triple Quadrupole Mass Spectrometer or the LCMS-2020 Single Quadrupole Mass Spectrometer creates a system for quick analysis of multiple samples with high accuracy.

Additional outstanding features

  • Efficient sample preparation
    through excellent injection repeatability with micro volume injections streamlining the preparation process.
  • Two or more analyzers share one system
    supporting the reduction of energy consumption and operation costs.
  • Column oven setting to the MS position
    enabling achievement of ultra-high-speed, high-separation LC/MS analysis while maximizing the system’s separation performance.

The Nexera MP is controlled by Shimadzu’s LabSolutions software and major LC/MS workstations available from other companies.

For more details please visit www.shimadzu.eu.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here